Challenges Facing Antitubercular Therapy: New Drugs and Delivery Systems

REFERENCES

• http://www.who.int/features/factfiles/tuberculosis/en/index.html
   Google Scholar
• http://www.who.int/features/mediacentre/factsheets/fs104/en/index.html
   Google Scholar
• Sheila SK, Paul HS, Prasanta C, Pryce LH, Hellen LC, Agnes KF, Richard DA, Stephen LG, John H, David GR. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994; 5147: 678–681
   Google Scholar
• Ferrari G, Langen H, Naito M, Pieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 1999; 97: 435–447
   PubMed Web of Science ®Google Scholar
• Walburger A, Koul A, Ferrari G, Nguyen L, Baschong CP, Kris H, Klebel B, Thompson C, Gerald B, Pieters J. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Sci 2004; 304: 1800–1804
   PubMed Web of Science ®Google Scholar
• Neu HC, Gootz TD. Antimicrobial chemotherapy. Medical microbiology, 4th, S Baron, RC Peake, DA James, M Susman, CA Kennedy, MJD Singleton, S Schuenke. The University of Texas Medical Branch at Galveston, Galveston, TX 1996; 121–145
   Google Scholar
• Miller LP, Crawford J T, Shinnick T M. The rpo B gene of mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 805–811
   PubMed Web of Science ®Google Scholar
• Caroline L, Maria G, Aina S, Helen BJ, Janet F. Molecular aharacterization of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Australia. Antimicrob Agents Chemother. 2005; 49: 4068–4074
   PubMed Web of Science ®Google Scholar
• Sharma SK, Mohan A. Multidrug-resistant tuberculosis. A menace that threatens to destabilize tuberculosis control. Chest 2006; 130: 260–272
   Google Scholar
• Singh S, Mariappan T, Sankar R, Sarda N, Baljinder S. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products and the likely solutions to the problem. Int J Pharm 2001; 228: 5–17
   PubMedGoogle Scholar
• Ramesh P, Shrutidevi A. Commentary biopharmaceutical and pharmacokinetic aspects of variable bioavailability of Rifampicin. Int J Pharm 2004; 271: 1–4
   PubMedGoogle Scholar
• Prema G, Geetha R, Hemanth AK, Rajasekaran S, Padmapriyadarsini C, Soumya S, Bhagavathy S, Venkatesan L, Sekar A, Mahilmaran N, Ravichandran Paramesh P. Decreased bioavailability of rifampicin and other anti-tuberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004; 48: 4473–4475
   PubMed Web of Science ®Google Scholar
• Klemens SP, Cynamon MH. In-vivo activities of newer rifamycin analogs against mycobacterium avium infection. Antimicrob Agents Chemother 1991; 35: 2026–2030
   PubMed Web of Science ®Google Scholar
• Reynaldo D, Lucileia T, Liamarcia CR, Moises P, Johnson J L, Charles W, Lynn R, Kathleen E, Jerrold JE. Safety, bactericidal activity of Rifalazil in patients in pulmonary tuberculosis. Antimicrob Agents Chemother 2001; 45: 1972–1976
   PubMed Web of Science ®Google Scholar
• Dutt M, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly(DL-Lactic-CD-glycolide) nanoparticles, Antimicrob Agents chemother 2001; 47: 829–835
   Google Scholar
• Klemens SP, Sharpe CA, Rogge MA, Cynamon MH. Activity of levofloxacin in murine model of tuberculosis. Antimicrob Agents Chemother 1994; 38: 1476–1479
   PubMed Web of Science ®Google Scholar
• Molnar J, Beladi I, Foldes I. Studies on antitubercular action of some phenothiazine derivatives in vitro. Zbl Bakt Hyg I Abt Orig. A. 1977; 239: 521–526
   PubMedGoogle Scholar
• Crowle AJ, Douvas GS, May MH. Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherappy 1992; 38: 410–419
   PubMed Web of Science ®Google Scholar
• Ratnakar P, Murthy P. Antitubercular activity of trifluoperazine: a calmodulin antagonist. FEMS Microbiol Lett 1992; 76: 73–76
   PubMedGoogle Scholar
• Chakrabarty AN, Bhattacharya CP, Dastidar SG. Antimycobacterial activity of methdilazine (Md), an antimicrobial phenothiazine. Acta Pathol Microbiol Immunol Scand 1993; 101: 449–454
   PubMed Web of Science ®Google Scholar
• Amaral L, Kristiansen JE, Abebe LS, Millet W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996; 38: 1049–1053
   PubMed Web of Science ®Google Scholar
• Kristiansen JE. The antimicrobial activity of non-antibiotics. Acta Pathol Microbiol Scand 1992; 100: 7–19
   Google Scholar
• Mazumdar R, Ganguly K, Dastidar SG, Chakrabarty AN. Trifluoperazine: a broad-spectrum bactericide specially active on staphylococci and vibrios. Int J Antimicrob Agents 2001; 18: 403–406
   PubMed Web of Science ®Google Scholar
• Molnár J, Mandi Y, Király J. Antibacterial effect of some phenothiazine compounds and the R-factor elimination by chlorpromazine. Acta Microbiol Acad Sci Hung 1976; 23: 45–54
   PubMedGoogle Scholar
• Annadurai S, Basu S, Ray S, Dastidar SG, Chakrabarty AN. Antimicrobial activity of the antiinflammatory agent diclofenac sodium. Indian J Exp Biol 1998; 36: 86–90
   PubMedGoogle Scholar
• Annadurai S, Guha-Thakurta A, Sa B, Dastidar SG, Ray R, Chakrabarty AN. Experimental studies on synergism between aminoglycosides and the antimicrobial anti-inflammatory agent diclofenac sodium. J Chemother 2002; 14: 47–53
   PubMed Web of Science ®Google Scholar
• Noton K, Sujata G D, Asok K, Kaushiki M, Raja R, Atindra N, Chakrabarty AN. Antimycobacterial activity of the anti-inflammatory agent diclofenac sodium and its synergism with streptomycin. Braz J Microbiol 2004; 35: 316–329
   Web of Science ®Google Scholar
• Jeanette WP, Pamela TT, David B, Amelia SLY, Mahesh N, Xinyi N, Jeyaraj D, Sarah L, Veronique D, Mark S, Samiul H, Michael C, Neil S R, Xia Y, Beat W, Kathryn B, Thomas D, Kakoli M. Peptide deformylase inhibitors as potent anti-mycobacterial agents. Antimicrob Agents Chemother 2006; 50: 3665–3673
   PubMed Web of Science ®Google Scholar
• Anthony JH, Minmin YU, Theres G, Martin M, Rochelle JR, Edward NB, Shaun LJ. The structure of MbtI from mycobacterium Tuberculosis, the first enzyme in the biosynthesis of siderophore mycobactin, reveals it to be a salicylate synthase. J Bacteriol 2006; 188: 6081–6091
   PubMed Web of Science ®Google Scholar
• Zeng XM, Martin GP, Mariott C. The controlled delivery of drug to the lung. Int J Pharm 1995; 124: 149–164
   Web of Science ®Google Scholar
• Dutt M, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly (dl-lactide-co-glycolide) microparticles. J Antimicrob. Chemother 2001; 47: 829–835
   PubMed Web of Science ®Google Scholar
• Patton JS, Fishburn CS, Weers JG. The lung as a portal for entry of systemic drug delivery. Proc Am Thorac Soc 2004; 1: 338–344
   PubMedGoogle Scholar
• McCallion ON, Taylor KM, Thomas M, Taylor AJ. Nebulization of fluids of different physico-chemical properties with air-jet and ultrasonic nebulizers. Pharm Res 1995; 12: 1682–1688
   PubMed Web of Science ®Google Scholar
• Patrick OH, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000; 17: 955–961
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005; 85: 227–234
   PubMed Web of Science ®Google Scholar
• Sally-ann C. Carrier based strategies for targeting protein and peptide drugs to the lung. AAPS Journal 2005; l7: E20–E41
   Google Scholar
• O'Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med 2005; 26: 327–340
   PubMed Web of Science ®Google Scholar
• Philip O, Alimuddin Z, Isabella R, Roxana R, Peter M, Melba G, John MG. Treatment of tuberculosis; present status and future prospects. Bull WHO 2005; 83: 857–865
   PubMed Web of Science ®Google Scholar
• Gupta P, Hameed S, Jain R. Heterocyclic compounds ring-substituted imidazoles as a new class of anti-tuberculosis agents. ChemInform, 36(1), online.
   Google Scholar